Presentation of Dr Jari Kempers on Economic Analysis of Generic Substitution of Antihypertensive Medicines in Moldova. How much would a mandatory generic drug substitution policy save? What are the impacts on the National Health Insurance Company’s (CNAM) drug reimbursement budget and patients’ co-payments?
Substitution of original medicines with their generic equivalents is a key cost-containment strategy used in most of the countries in Europe. In Moldova, the raising drug reimbursement costs pose challenges to the financing of the healthcare system. However, an effective generic substitution policy is not in place yet.
This policy brief assesses the potential cost-savings generated by mandatory generic substitution of antihypertensive (AHT) medicines in Moldova and predicts the impacts on the National Health Insurance Company (CNAM) reimbursement budget and patients’ co-payments. The objective of this policy brief is to open policy discussion with this practical example of AHT drugs.